Drug Profile

Clotrimazole - SALVAT

Alternative Names: SVT-15652

Latest Information Update: 23 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SALVAT
Class Antifungals; Chlorobenzenes; Imidazoles; Small molecules
Mechanism of Action 14-alpha demethylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Otitis externa
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase III Otitis externa

Most Recent Events

23 Sep 2022 Phase III development is ongoing for Otis externa (Otic) in Bulgaria, Portugal, Romania, Spain and USA (SALVAT pipeline, September 2022)
23 Sep 2022 SALVAT anticipates the launch of clotrimazole for Otitis externa (Otic) in 2023 (SALAVAT pipeline, September 2022)
09 Jun 2020 Phase-III clinical trials in Otitis externa (In adults, In the elderly) in Spain (Otic) (NCT03686397)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com